Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe , ... , today announced that it now offers the revolutionary ... CPAPs are the first sleep apnea therapy devices with ... and easy to track and share real-time data on ... of their CPAP therapy.  In addition, the internal modem ...
(Date:9/30/2014)... The Chinese wound care market is in ... the incidence of lifestyle diseases, coupled with the increase ... better quality of wound care products provide the impetus ... public health insurance schemes and increased reimbursement rate for ... the findings of primary and secondary researches, this research ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), ... for the sale of Gastrodia valued at 67.5 Million ... are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe ... of 550 tons of Gastrodia from January 1, 2012 to December ...
... Accuray Incorporated (Nasdaq: ARAY ), the ... study demonstrating the benefits of the CyberKnife® Robotic ... the treatment of central lung tumors using gantry based ... a great deal of accuracy to avoid risks of ...
Cached Medicine Technology:China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 2Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 3Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors 4
(Date:9/30/2014)... partnership funded by the Department of Defense (DoD) ... better-run clinical trials and may lead to the ... condition affecting not only athletes and soldiers, but ... youngsters to elders. , Under the partnership, ... million, five-year award from the DoD, the research ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Life Length ... provides CHL access to Life Length’s proprietary Telomere Analysis ... and comprehensive telomere test on the market today, and ... the percentage of short telomeres, providing the most critical ... Chairman of the Department of Cell Biology at The ...
(Date:9/30/2014)... 2014 Market Research Report on ... professional and in-depth market survey on Global and ... basic information of Cialis including its classification, application ... and China’s top manufacturers of Cialis listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
Breaking Medicine News(10 mins):Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3
... HIV case in Libya involving five Bulgarian nurses and a ... that they were tortured brutally to give false testimonies. ... when they were accused of starting an HIV epidemic in ... the infections have begun much before the arrival of these ...
... the better your heart health. But a man’s heart ... relationships among cholesterol levels,// psychological function, and neurologic disorders ... Harvard Men’s Health Watch. ,There are ... disease. Vascular dementia results when blood vessel damage deprives ...
... launched ‘The HumaPen Memoir’ the world's first digital insulin pen ... simplifies the management of diabetic patients who require timely insulin ... designed to meet the needs of people with diabetes who ... ,The unique pen memory device can help the patient to ...
... select patients for further testing may increase detection of ... colorectal cancer at a young age, //researchers report in ... National Cancer Institute. ,Lynch syndrome, also known ... mutations in DNA mismatch repair genes, the genes that ...
... key signaling protein in the brain during infancy could ... //According to findings published today in the journal Nature, ... serotonin just after birth exhibit abnormal anxiety as adults. ... mice genetically engineered to lack the receptor for serotonin, ...
... cases of dengue fever were reported across Paraguay in the ... new //cases a day last week, Paraguay's health authorities said ... has not yet declared the epidemic to be a health ... ,Dengue fever is a viral infection spread by the ...
Cached Medicine News:Health News:Mouse Study Suggests Anxiety Disorders Take Root in Infancy 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: